| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Medicine Branch, National Cancer Institute, Bethesda, Maryland 20892
1 To whom requests for reprints should be addressed, at Medicine Branch, National Cancer Institute, Building 10, Room 12N226, 9000 Rockville Pike, Bethesda, MD 20892.
A human breast cancer cell line (MCF7/WT) was selected for resistance to etoposide (VP-16) by stepwise exposure to 2-fold increasing concentrations of this agent. The resulting cell line (MCF7/VP) was 28-, 21-, and 9-fold resistant to VP-16, VM-26, and doxorubicin, respectively. MCF7/VP cells also exhibited low-level cross-resistance to 4'-(9-acridinylamino)-methanesulfon-m-anisidide, mitoxantrone, and vincristine and no cross-resistance to genistein and camptothecin. Furthermore, these cells were collaterally sensitive to the alkylating agents melphalan and chlorambucil. DNA topoisomerase II levels were similar in both wild-type MCF7/WT and drug-resistant MCF7/VP cells. In contrast, topoisomerase II from MCF7/VP cells appeared to be 7-fold less sensitive to drug-induced cleavable complex formation in whole cells and 3-fold less sensitive in nuclear extracts than topoisomerase II from MCF7/WT cells. Although this suggested that the resistant cells may contain a qualitatively altered topoisomerase II, no mutations were detected in either the ATP-binding nor the putative breakage/resealing regions of either DNA topoisomerase II
or IIβ. In addition, the steady-state intracellular VP-16 concentration was reduced by 2-fold in the resistant cells, in the absence of detectable mdr1/P-gp expression and without any change in drug efflux. In contrast, expression of the gene encoding the MRP was increased at least 10-fold in resistant MCF7/VP cells as compared to sensitive MCF7/WT cells. These results suggest that resistance to epipodophyllotoxins in MCF7/VP cells is multifactorial, involving a reduction in intracellular drug concentration, possibly as a consequence of MRP overexpression, and an altered DNA topoisomerase II drug sensitivity.
2 Present address: Sealy Center for Molecular Science, University of Texas Medical Branch, Galveston, TX 77555.
3 Present address: Department of Urology, Oita Medical University, Hazama-cho, Oita 879-55, Japan.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received 4/30/93. Accepted 11/ 1/93.
This article has been cited by other articles:
|
|
 |
|
  C. A. Burkhart, F. Watt, J. Murray, M. Pajic, A. Prokvolit, C. Xue, C. Flemming, J. Smith, A. Purmal, N. Isachenko, et al. Small-Molecule Multidrug Resistance-Associated Protein 1 Inhibitor Reversan Increases the Therapeutic Index of Chemotherapy in Mouse Models of Neuroblastoma Cancer Res., August 15, 2009; 69(16): 6573 - 6580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Liao, R. W. Robey, J. Guirouilh-Barbat, K. K. W. To, O. Polgar, S. E. Bates, and Y. Pommier Reduced Expression of DNA Topoisomerase I in SF295 Human Glioblastoma Cells Selected for Resistance to Homocamptothecin and Diflomotecan Mol. Pharmacol., February 1, 2008; 73(2): 490 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. P. Gan, E. Pasquier, and M. Kavallaris Class III {beta}-Tubulin Mediates Sensitivity to Chemotherapeutic Drugs in Non Small Cell Lung Cancer Cancer Res., October 1, 2007; 67(19): 9356 - 9363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kasibhatla, V. Baichwal, S. X. Cai, B. Roth, I. Skvortsova, S. Skvortsov, P. Lukas, N. M. English, N. Sirisoma, J. Drewe, et al. MPC-6827: A Small-Molecule Inhibitor of Microtubule Formation That Is Not a Substrate for Multidrug Resistance Pumps Cancer Res., June 15, 2007; 67(12): 5865 - 5871. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Whitnall, J. Howard, P. Ponka, and D. R. Richardson A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics PNAS, October 3, 2006; 103(40): 14901 - 14906. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Deeley, C. Westlake, and S. P. C. Cole Transmembrane Transport of Endo- and Xenobiotics by Mammalian ATP-Binding Cassette Multidrug Resistance Proteins. Physiol Rev, July 1, 2006; 86(3): 849 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Watts, C. Hawkins, P. Ponka, and D. R. Richardson Nitrogen monoxide (NO)-mediated iron release from cells is linked to NO-induced glutathione efflux via multidrug resistance-associated protein 1 PNAS, May 16, 2006; 103(20): 7670 - 7675. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Morrow, C. Peklak-Scott, B. Bishwokarma, T. E. Kute, P. K. Smitherman, and A. J. Townsend Multidrug Resistance Protein 1 (MRP1, ABCC1) Mediates Resistance to Mitoxantrone via Glutathione-Dependent Drug Efflux Mol. Pharmacol., April 1, 2006; 69(4): 1499 - 1505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-H. Yang, C.-J. Huang, C.-S. Yang, Y.-C. Chu, A.-L. Cheng, J. Whang-Peng, and P.-C. Yang Gefitinib Reverses Chemotherapy Resistance in Gefitinib-Insensitive Multidrug Resistant Cancer Cells Expressing ATP-Binding Cassette Family Protein Cancer Res., August 1, 2005; 65(15): 6943 - 6949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. He, P. L. R. Ee, J. S. Coon, and W. T. Beck Alternative Splicing of the Multidrug Resistance Protein 1/ATP Binding Cassette Transporter Subfamily Gene in Ovarian Cancer Creates Functional Splice Variants and Is Associated with Increased Expression of the Splicing Factors PTB and SRp20 Clin. Cancer Res., July 15, 2004; 10(14): 4652 - 4660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. A. Plasschaert, D. M. van der Kolk, E. S. J. M. de Bont, W. A. Kamps, K. Morisaki, S. E. Bates, G. L. Scheffer, R. J. Scheper, E. Vellenga, and E. G. E. de Vries The Role of Breast Cancer Resistance Protein in Acute Lymphoblastic Leukemia Clin. Cancer Res., November 1, 2003; 9(14): 5171 - 5177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. French, R. S. Schrecengost, B. D. Lee, Y. Zhuang, S. N. Smith, J. L. Eberly, J. K. Yun, and C. D. Smith Discovery and Evaluation of Inhibitors of Human Sphingosine Kinase Cancer Res., September 15, 2003; 63(18): 5962 - 5969. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Lockhart, R. G. Tirona, and R. B. Kim Pharmacogenetics of ATP-binding Cassette Transporters in Cancer and Chemotherapy Mol. Cancer Ther., July 1, 2003; 2(7): 685 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Mercatante, J. L. Mohler, and R. Kole Cellular Response to an Antisense-mediated Shift of Bcl-x Pre-mRNA Splicing and Antineoplastic Agents J. Biol. Chem., December 13, 2002; 277(51): 49374 - 49382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Volk, K. M. Farley, Y. Wu, F. Li, R. W. Robey, and E. Schneider Overexpression of Wild-Type Breast Cancer Resistance Protein Mediates Methotrexate Resistance Cancer Res., September 1, 2002; 62(17): 5035 - 5040. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Seiden, S.-W. Ng, J. G. Supko, D. P. Ryan, J. W. Clark, T. Lynch, K.-C. Huang, D. Kwiatkowski, A. Skarin, and J. P. Eder Jr. A Phase I Clinical Trial of Sequentially Administered Doxorubicin and Topotecan in Refractory Solid Tumors Clin. Cancer Res., March 1, 2002; 8(3): 691 - 697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rajagopal, A. C. Pant, S. M. Simon, and Y. Chen In Vivo Analysis of Human Multidrug Resistance Protein 1 (MRP1) Activity Using Transient Expression of Fluorescently Tagged MRP1 Cancer Res., January 1, 2002; 62(2): 391 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Diah, P. K. Smitherman, J. Aldridge, E. L. Volk, E. Schneider, A. J. Townsend, and C. S. Morrow Resistance to Mitoxantrone in Multidrug-resistant MCF7 Breast Cancer Cells: Evaluation of Mitoxantrone Transport and the Role of Multidrug Resistance Protein Family Proteins Cancer Res., July 1, 2001; 61(14): 5461 - 5467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Robey, W. Y. Medina-Pérez, K. Nishiyama, T. Lahusen, K. Miyake, T. Litman, A. M. Senderowicz, D. D. Ross, and S. E. Bates Overexpression of the ATP-binding Cassette Half-Transporter, ABCG2 (MXR/BCRP/ABCP1), in Flavopiridol-resistant Human Breast Cancer Cells Clin. Cancer Res., January 1, 2001; 7(1): 145 - 152. [Abstract] [Full Text]
|
|
|
|
|
|
D. M. van der Kolk, E. G. E. de Vries, W. L. J. van Putten, L. F. Verdonck, G. J. Ossenkoppele, G. E. G. Verhoef, and E. Vellenga P-glycoprotein and Multidrug Resistance Protein Activities in Relation to Treatment Outcome in Acute Myeloid Leukemia Clin. Cancer Res., August 1, 2000; 6(8): 3205 - 3214. [Abstract] [Full Text]
|
|
|
|
|
|
E. L. Volk, K. Rohde, M. Rhee, J. J. McGuire, L. A. Doyle, D. D. Ross, and E. Schneider Methotrexate Cross-Resistance in a Mitoxantrone-selected Multidrug-resistant MCF7 Breast Cancer Cell Line Is Attributable to Enhanced Energy-dependent Drug Efflux Cancer Res., July 1, 2000; 60(13): 3514 - 3521. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Newman, J. C. Rodarte, K. D. Benbatoul, S. J. Romano, C. Zhang, S. Krane, E. J. Moran, R. T. Uyeda, R. Dixon, E. S. Guns, et al. Discovery and Characterization of OC144-093, a Novel Inhibitor of P-Glycoprotein-mediated Multidrug Resistance Cancer Res., June 1, 2000; 60(11): 2964 - 2972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Bello-Reuss, S. Ernest, O. B. Holland, and M. R. Hellmich Role of multidrug resistance P-glycoprotein in the secretion of aldosterone by human adrenal NCI-H295 cells Am J Physiol Cell Physiol, June 1, 2000; 278(6): C1256 - C1265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kornmann, K. D. Danenberg, N. Arber, H. G. Beger, P. V. Danenberg, and M. Korc Inhibition of Cyclin D1 Expression in Human Pancreatic Cancer Cells Is Associated with Increased Chemosensitivity and Decreased Expression of Multiple Chemoresistance Genes Cancer Res., July 1, 1999; 59(14): 3505 - 3511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Ross, W. Yang, L. V. Abruzzo, W. S. Dalton, E. Schneider, H. Lage, M. Dietel, L. Greenberger, S. P. C. Cole, and L. A. Doyle Atypical Multidrug Resistance: Breast Cancer Resistance Protein Messenger RNA Expression in Mitoxantrone-Selected Cell Lines J Natl Cancer Inst, March 3, 1999; 91(5): 429 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Alvarez, R. Robey, V. Sandor, K. Nishiyama, Y. Matsumoto, K. Paull, S. Bates, and T. Fojo Using the National Cancer Institute Anticancer Drug Screen to Assess the Effect of MRP Expression on Drug Sensitivity Profiles Mol. Pharmacol., November 1, 1998; 54(5): 802 - 814. [Abstract] [Full Text]
|
|
|
|
|
|
C. S. Morrow, P. K. Smitherman, S. K. Diah, E. Schneider, and A. J. Townsend Coordinated Action of Glutathione S-Transferases (GSTs) and Multidrug Resistance Protein 1 (MRP1) in Antineoplastic Drug Detoxification. MECHANISM OF GST A1-1- AND MRP1-ASSOCIATED RESISTANCE TO CHLORAMBUCIL IN MCF7 BREAST CARCINOMA CELLS J. Biol. Chem., August 7, 1998; 273(32): 20114 - 20120. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zhan, V. A. Sandor, E. Gamelin, J. Regis, B. Dickstein, W. Wilson, A. T. Fojo, and S. E. Bates Expression of the Multidrug Resistance-Associated Protein Gene in Refractory Lymphoma: Quantitation by a Validated Polymerase Chain Reaction Assay Blood, May 15, 1997; 89(10): 3795 - 3800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Sumizawa, Z.-S. Chen, Y. Chuman, K. Seto, T. Furukawa, M. Haraguchi, A. Tani, N. Shudo, and S.-I. Akiyama Reversal of Multidrug Resistance-Associated Protein-Mediated Drug Resistance by the Pyridine Analog PAK-104P Mol. Pharmacol., March 1, 1997; 51(3): 399 - 405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gao, D. W. Loe, C. E. Grant, S. P.C. Cole, and R. G. Deeley Reconstitution of ATP-dependent Leukotriene C4 Transport by Co-expression of Both Half-molecules of Human Multidrug Resistance Protein in Insect Cells J. Biol. Chem., November 1, 1996; 271(44): 27782 - 27787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Goldsmith, J. M. Gudas, E. Schneider, and K. H. Cowan Wild Type p53 Stimulates Expression from the Human Multidrug Resistance Promoter in a p53-negative Cell Line J. Biol. Chem., January 27, 1995; 270(4): 1894 - 1898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Paumi, B. G. Ledford, P. K. Smitherman, A. J. Townsend, and C. S. Morrow Role of Multidrug Resistance Protein 1 (MRP1) and Glutathione S-Transferase A1-1 in Alkylating Agent Resistance. KINETICS OF GLUTATHIONE CONJUGATE FORMATION AND EFFLUX GOVERN DIFFERENTIAL CELLULAR SENSITIVITY TO CHLORAMBUCIL VERSUS MELPHALAN TOXICITY J. Biol. Chem., March 9, 2001; 276(11): 7952 - 7956. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
